Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer

Jingsong Zhang, Jessica J. Cunningham, Joel S. Brown, View ORCID ProfileRobert A. Gatenby
doi: https://doi.org/10.1101/2021.11.30.21267059
Jingsong Zhang
1Department of Genitourinary Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica J. Cunningham
2Department of Integrated Mathematical Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel S. Brown
2Department of Integrated Mathematical Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
3Department of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Gatenby
2Department of Integrated Mathematical Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
4Cancer Biology and Evolution Program, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert A. Gatenby
  • For correspondence: Robert.Gatenby{at}moffitt.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We present a multidisciplinary approach to clinical trial design and analysis in a pilot study (NCT02415621) in which evolution-based mathematical models guide patient-specific dosing for Abiraterone treatment in men with castrate resistant metastatic prostate cancer.

Methods Abiraterone plus prednisone were administered intermittently based on an evolutionary mathematical model. Outcomes are compared to historical controls and a matched contemporaneous cohort who met trial eligibility but received SOC dosing. Longitudinal cohort data allowed modification of pre-trial model parameter estimates. Model simulations of each patient using updated parameters critically evaluated trial design.

Results Trial patients, on average, received no abiraterone during 59% of time on treatment. Median Time to Radiographic Progression (TTP) was 30.4 months compared to 14.3 months in the contemporaneous SOC group (p<0.001). All patients in the SOC group have progressed but 4 in the adaptive cohort remain on treatment at >1800 days. Longitudinal trial data found the competition coefficient ratio (αRS/αSR) of sensitive and resistant populations, a critical factor in intratumoral evolution, was 2 to 3-fold higher than pre-trial estimates. Computer simulations using the corrected parameter unexpectedly demonstrated optimal cycling can reduce the resistant cells. Longitudinal data from 4 trial patients who remain on treatment are consistent with model predictions. Modeling results predict protocol changes that will allow similar outcomes in most patients.

Conclusions Administration of abiraterone using evolution-based mathematical models decreased drug dosing and increased radiographic TTP. Integration of mathematical models into trial design identifies novel insights into key treatment parameters and provides optimization strategies for follow-up investigations.

Article Summary supplemental sections outline the methodology for parameter estimates from trial data, computer simulations, and comparison of simulation results and actual clinical data in every patient in both cohorts.

Statement of Translational Relevance Integration of evolution-based mathematical models significantly increased TTP in abiraterone therapy for mCRPC. This multidisciplinary approach represents a novel clinical trial strategy in which the treatment protocol is framed mathematically, clinical data then refines model parameterization, and simulations using the updated model predict alternative strategies to improve outcomes. Here we demonstrate the mathematical models used to design the trial can also produce novel analytic approaches. By using longitudinal trial data, key model parameters can be refined. Simulations using the updated model can then be applied to every patient in the trial. Finally, additional simulations demonstrate alternative protocols that could improve results. These analyses demonstrate evolution-based approaches may allow consistent long-term control in patients with metastatic prostate cancer.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT02415621

Funding Statement

This work was supported by the James S. McDonnell Foundation grant Cancer therapy: Perturbing a complex adaptive system grants from the Jacobson Foundation NIH/National Cancer Institute (NCI) R01CA170595, Application of Evolutionary Principles to Maintain Cancer Control (PQ21), and NIH/NCI U54CA143970-05 (Physical Science Oncology Network (PSON)) Cancer as a complex adaptive system. This work has also been supported in part by the Clinical Trials Core Facility at the H. Lee Moffitt Cancer Center and Research Institute an NCI-designated Comprehensive Cancer Center (P30-CA076292) and the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 690817.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Moffitt Cancer Center gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding This work was supported by the James S. McDonnell Foundation grant, “Cancer therapy: Perturbing a complex adaptive system,” grants from the Jacobson Foundation, NIH/National Cancer Institute (NCI) R01CA170595, Application of Evolutionary Principles to Maintain Cancer Control (PQ21), and NIH/NCI U54CA143970-05 (Physical Science Oncology Network (PSON)) “Cancer as a complex adaptive system”. This work has also been supported in part by the Clinical Trials Core Facility at the H. Lee Moffitt Cancer Center and Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292), and the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 690817.

  • Conflict of Interests The authors declare no conflict of interests.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer
Jingsong Zhang, Jessica J. Cunningham, Joel S. Brown, Robert A. Gatenby
medRxiv 2021.11.30.21267059; doi: https://doi.org/10.1101/2021.11.30.21267059
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer
Jingsong Zhang, Jessica J. Cunningham, Joel S. Brown, Robert A. Gatenby
medRxiv 2021.11.30.21267059; doi: https://doi.org/10.1101/2021.11.30.21267059

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (754)
  • Anesthesia (221)
  • Cardiovascular Medicine (3287)
  • Dentistry and Oral Medicine (363)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13355)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5144)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3263)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14619)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4917)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2518)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4202)
  • Public and Global Health (7495)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (205)